Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Journal: Nature Medicine

Published: 2020-08-03

DOI: 10.1038/s41591-020-1008-z

Affiliations: 60

Authors: 79

Go to article
Institutions Share
Department of Pathology and Tumor Biology, Kyoto University, Japan 0.06
Center for Hematology and Regenerative Medicine (HERM), KI, Sweden 0.05
Department of Epidemiology and Biostatistics, MSKCC, United States of America (USA) 0.05
Center for Hematologic Malignancies, MSKCC, United States of America (USA) 0.05
University Medical Center Göttingen (UMG), Germany 0.04
Department of Medicine, MSKCC, United States of America (USA) 0.04
Computational Oncology Service, MSKCC, United States of America (USA) 0.04
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, MHH, Germany 0.03
Integrated Genomics Operation (IGO), MSKCC, United States of America (USA) 0.03
Faculty of Medicine, HHU, Germany 0.03
NIHR Oxford Biomedical Research Centre (OxBRC), United Kingdom (UK) 0.03
University of Paris, France 0.03
Josep Carreras Leukaemia Research Institute (IJC), Spain 0.03
Department of Data Sciences, DFCI, United States of America (USA) 0.03
La Fe University Hospital, Spain 0.02
Moores Cancer Center, UC San Diego, United States of America (USA) 0.01
Institute of Hematology and Blood Transfusion (IHBT), Czech Republic 0.01
Hôpital Saint-Louis, France 0.01
Cancer Center, IRCCS Humanitas Research Hospital, Italy 0.01
Department of Health Sciences, University of York, United Kingdom (UK) 0.01
Radboud University Medical Centre (Radboudumc), RU, Netherlands 0.01
Faculty of Medicine, Leipzig University, Germany 0.01
Ludwig Boltzmann Institute for Hematology and Oncology (LBI-HO), Austria 0.01
University of Rochester Medical Center (URMC), UR, United States of America (USA) 0.01
Sant'Orsola Malpighi Hospital, Italy 0.01
Department of Medical Oncology, DFCI, United States of America (USA) 0.01
Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), Japan 0.01
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Italy 0.01
Faculty of Medicine, University of Tsukuba, Japan 0.01
Chugoku Central Hospital, Japan 0.01
Stanford Cancer Institute (SCI), United States of America (USA) 0.01
Faculdade de Medicina, UFC, Brazil 0.01
Department of Pathology, MGH, United States of America (USA) 0.01
non-affiliated author contributions, Austria 0.01
Department of Molecular Medicine, UNIPV, Italy 0.01
IRCCS Policlinico San Matteo, Italy 0.01
St James's University Hospital, United Kingdom (UK) 0.01
Department of Pathology, MSKCC, United States of America (USA) 0.01
Department of Hematology, VUmc, Netherlands 0.01
Cochin Hospital, France 0.01
Department of Biomedical and Neuromotor Sciences (DIBINEM), UNIBO, Italy 0.01
Careggi University Hospital (AOUC), UNIFI, Italy 0.01
Faculty of Health Sciences, DUTH, Greece 0.01
Hospital Israelita Albert Einstein, Brazil 0.01
Gifu Municipal Hospital, Japan 0.01
Kobe City Medical Center General Hospital, Japan 0.01
Graduate School of Medicine, Gifu University, Japan 0.01
Department of Hematology and Oncology, Kyoto University, Japan 0.01
Faculty of Medicine, CU, Thailand 0.01
Department of Hematology, Nagasaki University, Japan 0.01
Atomic Bomb Disease Institute, Nagasaki University, Japan 0.01
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain 0.01
Linkou Chang Gung Memorial Hospital, Chang Gung Medical Foundation, Taiwan 0.01
Chang Gung University (CGU), Taiwan 0.01
Vanderbilt-Ingram Cancer Center (VICC), VU, United States of America (USA) 0.01
School of Medicine, VU, United States of America (USA) 0.01
King Chulalongkorn Memorial Hospital, Thailand 0.01

Return